GlaxoSmithKline: Migraine Disorders trials

The registry lists 28 Migraine Disorders studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 2Phase 2 3Phase 3 13Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treximet ™ Pharmacy Budget Impact Model Database Validation StudyCompletedNCT01332500Results posted
• Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and AdolescentsCompletedNCT00963937Phase 3Results posted
• Migraine Study in Adolescent PatientsCompletedNCT00843024Phase 3Results posted
• A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month PeriodCompletedNCT00792636Phase 4Results posted
• TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in AdultsCompletedNCT00573170Phase 3Results posted
• Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in AdolescentsCompletedNCT00488514Phase 3Results posted
• TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)CompletedNCT00387881Phase 3Results posted
• TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a MigraineCompletedNCT00385008Phase 3Results posted
• A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)CompletedNCT00383162Phase 3Results posted
• A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)CompletedNCT00382993Phase 3Results posted
• Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In JapanCompletedNCT00356603Phase 3Results posted
• Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic MigraineCompletedNCT01435941
• A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World DataCompletedNCT01381523
• Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan MonotherapyCompletedNCT01381497
• Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) TabletCompletedNCT01376193
• Drug Use Investigation for IMIGRAN TabletCompletedNCT01376141
• Special Drug Use Investigation for AMERGE® Tablet (Long-term)CompletedNCT01332383
• Sumatriptan and Naratriptan Pregnancy RegistryCompletedNCT01059604
• A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.CompletedNCT00989625Phase 1
• An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)CompletedNCT00875784Phase 1
• Clinical Study Of Migraine EvolutionCompletedNCT00460005
• Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With DysmenorrheaCompletedNCT00329459Phase 3
• Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)CompletedNCT00329355Phase 3
• An Adaptive Design Trial Of GW274150 In The Treatment Of Acute MigraineCompletedNCT00319137Phase 2
• Use Of SB-705498 In The Acute Treatment Of MigraineCompletedNCT00269022Phase 2
• Use Of GW274150 In The Prophylactic Treatment Of MigraineCompletedNCT00242866Phase 2
• Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine AttacksCompletedNCT00240630Phase 3
• Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine AttacksCompletedNCT00240617Phase 3